Rituximab followed by mycophenolate mofetil in children with IgM nephropathy

Indian Pediatr. 2012 Oct;49(10):831-3. doi: 10.1007/s13312-012-0168-4.

Abstract

IgM nephropathy presents with refractory nephrotic syndrome and its treatment is a significant challenge for pediatricians. We present two patients with IgM nephropathy and frequently relapsing nephrotic syndrome treated with rituximab and subsequently mycophenolate mofetil. Both showed complete remission, which 24 to 30 months later, was still maintained. The role of mycophenolate mofetil therapy in maintaining remission after successful treatment of rituximab in IgM nephropathy needs to be examined.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Child, Preschool
  • Female
  • Humans
  • Immunoglobulin M*
  • Immunologic Factors / therapeutic use*
  • Infant
  • Male
  • Mycophenolic Acid / analogs & derivatives*
  • Mycophenolic Acid / therapeutic use
  • Nephrotic Syndrome / drug therapy*
  • Rituximab

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Immunoglobulin M
  • Immunologic Factors
  • Rituximab
  • Mycophenolic Acid